Key result
Chlorthalidone is recommended over hydrochlorothiazide as the evidence-based diuretic comparator in hypertension trials due to its longer half-life and proven cardiovascular benefits.
Answers are grounded in this paper and cite their sources.
The authors argue that chlorthalidone, rather than hydrochlorothiazide, should be the preferred evidence-based diuretic comparator in hypertension trials.
We have read the study design "Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active controlled, phase 4, randomized trial" by Oh GC, et al. with interest. The authors aim to compare the efficacy of amlodipine or hydrochlorothiazide (HCTZ) with an ARB. However, we wish to highlight that chlorthalidone (CTD) is the evidence-based and recommended anti-hypertensive diuretic, and should replace HCTZ in the trial to effectively compare efficacy against the CCB amlodipine.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2018) conducted a letter in Hypertension. Chlorthalidone vs. Hydrochlorothiazide was evaluated. Chlorthalidone is recommended over hydrochlorothiazide as the evidence-based diuretic comparator in hypertension trials due to its longer half-life and proven cardiovascular benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: